

Save a backup on your local computer (disable if you are using a public/shared computer)

Views

Standard 

Public consultation for the 2016 evaluation of the EU Drugs Strategy and Action Plan on Drugs

Language

[\[EN\] English](#)

Contact

Alina.RAT

[Download P](#)

Fields marked with * are mandatory.

* Please
choose from one of the following options on the use of your
contribution:

- My contribution can be directly published, with my personal/organisation information (I consent to publication of all information in my contribution in whole or in part including my name/the name of my organisation, and I declare that nothing within my response is unlawful or would infringe the rights of any third party in a manner that would prevent publication)
- My contribution can be directly published, provided that this is done anonymously. (I consent to publication of any information in my contribution in whole or in part (which may include quotes or opinions I express) and I declare that nothing within my response is unlawful or would infringe the rights of any third party in a manner that would prevent publication)
- My contribution cannot be directly published but may be included within statistical data (I understand that my contribution will not be directly published, but that my anonymised responses may be included in published statistical data). Note that your answers may be subject to a request for public access to documents under Regulation (EC) No 1049/2001

* If required, can the Commission services contact
you for further details on the information you have
submitted?

- Yes
 No

* 1. Are you submitting your contribution
as:

Only one choice is possible

- a private individual
- a national public authority
- an international/intergovernmental/regional organisation
- an organisation (non-governmental, civil society organisation, academia, research, social partner, interest group, consultancy, think-tank ...) or private company

* 2.

Please, provide your name and/or your organisation's name and contact
details:

200 character(s) maximum (200 characters left)

* 3.

The answers you will provide are expected to refer to a specific Member
State or to the EU as a whole. Please, select the option that best fits
your case:



* 4.

Please specify your level of involvement in the area of drug
policy:

- I am actively working in the field
- I am interested in the field without actively working in it

* 5.

Which of the following areas of drug-related policies best describes your
field of activity or
interest?

Multiple answer options can be selected

- Drug demand reduction
- Drug supply reduction
- Coordination of drug policies at international/EU level
- Coordination of drug policies at regional/national level
- Cooperation with non-EU countries and international organisations
- Information, research, monitoring and evaluation activities
- Other

[Login](#) | [About](#) | [Support](#) | [Download](#) | [Documentation](#)

***6. Did you take part in any activity related to the selected policy area(s) in the period 2013-2016?**

Multiple answer options can be selected

- no
- yes, in the definition of drug-related policies and/or legislation
- yes, in the implementation of drug-related policies and/or legislation
- yes, in the monitoring of drug-related policies and/or legislation
- yes, in the evaluation of drug-related policies and/or legislation factors

7. In your opinion, in the period 2013-2016 were measures implemented with the aim of:

	YES	NO	NO OPINION
*Delaying the first use of drugs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Preventing drug use by people with age, gender, cultural or social risk factors (e.g. through initiatives for children and teenagers in the schools, pregnant women, Roma population)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Preventing drug use by people with situational risk factors (e.g. homelessness, working and driving under the influence of drugs, drugs use in nightlife)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Preventing drug use by people with individual risk factors (e.g. multiple addictions, mental health problems, family circumstances)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Raising awareness on the misuse of and dependence on medicines	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Increasing the availability of drug treatment and rehabilitation services	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Increasing the accessibility of drug treatment and rehabilitation services	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Introducing best practices and quality approaches in drug demand reduction	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Reducing drug-related risk and harm (e.g. prevention of infectious diseases such as HIV, hepatitis C)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

8. In your opinion, to what extent has the effectiveness* of these measures changed during the period 2013-2016 compared to the period 2005-2012?

* Effectiveness: to what extent EU/national actions have achieved the expected results or contributed to progress in certain areas.

	IT IMPROVED	IT REMAINED THE SAME	IT GOT WORSE	NO OPINION
*Delay of the first use of drugs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Prevention of drugs use by people with age, gender, cultural or social risk factors (e.g. through initiatives for children and teenagers in the schools, pregnant women, Roma population)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Prevention of drugs use by people with situational risk factors (e.g. homelessness, working and driving under the influence of drugs, drugs use in nightlife)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Prevention of drugs use by people with individual risk factors (e.g. other addictions, mental health problems, family circumstances)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

EU Survey	EU Survey	EU Survey	EU Survey	EU Survey	Login About Support Download Documentation
The progress on the misuse of, and dependence on medicines *Availability and accessibility of treatment and rehabilitation services	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	
*Reduction of drug-related risk and harm (e.g. prevention of infectious diseases such as HIV, hepatitis C)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	

***9. In your opinion, what steps could be taken to improve the effectiveness of the drug demand reduction policies in the EU?**

Multiple answer options can be selected

- Adoption of more binding provisions and commitments at a national/regional level
- Development of deeper synergies between the EU and national measures
- Improvement of research, monitoring, collecting data and evaluation activity
- Stronger civil society and scientific community involvement
- Allocation of additional financial resources
- Other

10. In your opinion, in the period 2013-2016 were measures implemented with the aim of:

	YES	NO	NO OPINION
*Countering cross-border drug trafficking through the improvement of border security (e.g. in the airports or seaports)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Increasing legislative and judicial cooperation against cross-border illicit drug activities	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Preventing the diversion and illicit use of drug precursors	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Countering the emergence, use and spread of new psychoactive substances	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Developing sanctions other than detention for drug-using offenders (e.g. rehabilitation, social integration or education)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Responding to the use of new technologies in illicit drug activities (e.g. purchasing drugs online)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

11. In your opinion, to what extent has the effectiveness* of these measures changed during the period 2013-2016 compared to 2005-2012?

* Effectiveness: to what extent EU/national actions have achieved the expected results or contributed to progress in certain areas.

	IT IMPROVED	IT REMAINED THE SAME	IT GOT WORSE	NO OPINION
*Counter cross-border drug trafficking through the improvement of border security (e.g. in the airports or seaports)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Increase of legislative and judicial cooperation against cross-border illicit drug activities	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Prevention of the diversion and illicit use of drug precursors	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Contrast to the emergence, use and spread of new psychoactive substances	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Development of sanctions other than detention for drug-using offenders (e.g. rehabilitation, social integration or education)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Response to the use of new technologies in illicit drug activities (e.g. purchasing drugs online)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

12. In your opinion, what steps could be taken to improve the effectiveness of drug supply reduction policies in the EU?

Multiple answer options can be selected

- Adoption of more binding provisions and commitments at a national/regional level
- Development of deeper synergies between the EU and national measures
- Strengthening of the support to third countries in addressing drug-related organised crime
- Improvement of research, monitoring, collecting data and evaluation activity in the drugs field
- Stronger civil society and scientific community involvement
- Stronger involvement of industry and economic operators in preventing diversion of drug precursors
- Allocation of additional financial resources
- Other

13. In your opinion, in the period 2013-2016 were measures implemented with aim of:

	YES	NO	NO OPINION
*Coordinating drug policies and responses at a national level	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Involving the civil society and the scientific community in the development and implementation of drug policies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Cooperating with international organisations in the drug policies field	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Cooperating with non-EU countries in the drug policies field	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Information, research, monitoring and evaluation related to the drug phenomenon	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

14. In your opinion, to what extent has the effectiveness* of the following actions changed during the period 2013-2016 compared to 2005-2012?

* Effectiveness: to what extent EU/national actions have achieved the expected results or contributed to progress in certain areas.

	IT IMPROVED	IT REMAINED THE SAME	IT GOT WORSE	NO OPINION
*Coordination of drug policies and responses at a national level	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Involvement of the civil society and the scientific community in the development and implementation of drug policies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Investments in research, data collection, monitoring, evaluation and information exchange	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Dissemination of research, monitoring and evaluation results	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Cooperation with international organisations in the drug policies field	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Cooperation with third countries in the drug policies field	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*Visibility of the EU approach to drugs policy in the international arena	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

***15. In your opinion, what steps could be taken to improve the effectiveness of the EU international engagement in the drugs field?**

Multiple answer options can be selected

- Further integration of drug policies within the overall EU common and security foreign policy
-

EU Survey [Home](#) | [About](#) | [Support](#) | [Download](#) | [Documentation](#)
 Enhance dialogue with third countries and regional organisations on tackling drugs, including drug and drug precursors trafficking and drug demand reduction

- Review the priority countries for EU engagement on drugs with third countries
- Enhance coordination of EU positions on drug policy with selected countries at UN level
- Increase financial assistance for drug related cooperation (drug demand reduction and drug supply reduction) programmes with third countries
- Increase the synergy between policy dialogue and financial assistance on drug policies
- Mainstream alternative development into EU development programmes with third countries
- Further explore the links between drugs trafficking and other forms of international organised crime (e.g. terrorism, human trafficking, smuggling, ...)
- Provide for increased EU funding to alternative development programmes

16. In your opinion, what is the EU Drugs Strategy's added value? Please indicate how much you agree with the following statements, on a scale from 1 to 4, where 1 means "I do not agree at all" and 4 means "I fully agree"

	1	2	3	4
*It supports the development of a dialogue and/or a consistent approach to drugs at national level	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*It helps to raise important debates on drug policies on the international agenda	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*It helps to improve coherence between national/regional and European drug-related actions	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*It facilitates the allocation of a larger amount of national public resources to specific activities or initiatives in the drug field	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*It helps to improve the involvement of civil society and scientific community in drug policies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
*The Strategy has no significant added value	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

*** 17. In the future, where do you see the focus of the EU's drugs policy?**

at most 5 choice(s)

- Prevention
- Treatment and rehabilitation services
- Risk and harm reduction
- Finding synergies between drugs use and other addictions (e.g. alcohol, tobacco, gambling) and addressing them altogether
- Fighting against drugs trafficking, drug precursors diversion and other kinds of organised crime
- Analysing the links between drug trafficking and other major and serious crimes
- Tackling online trade of drugs
- Reinforcing the EU and international response to the spread of new psychoactive substances
- Coordination of drug policies at EU and national/regional/local levels
- Stronger involvement of the EU in addressing world drug challenges
- Strengthening cooperation with non-EU countries and international organisations on drug policies (on both drug demand and drug supply reduction)
- Strengthen the promotion of EU values and approaches
- Promotion of scientific research on drugs
- Monitoring, evaluation, data collection, information and best practices exchange
- Address cannabis at EU level
- I don't think there is a need for future EU action in this domain
- Other

*** 18. Please explain your reasoning for your answer to question 17.**

600 character(s) maximum (600 characters left)

EUSurvey is supported by the European Commission's ISA programme, which promotes interoperability solutions for European public administrations. [Login](#) | [About](#) | [Support](#) | [Download](#) | [Documentation](#)